When a company gets delisted from a major stock exchange, most people assume the worst. The immediate reaction is often: the company is failing, shares are worthless, and a bankruptcy filing is just around the corner. That reaction is understandable — but it is frequently wrong.
Zomedica’s removal from NYSE American triggered exactly that kind of concern. This article explains what actually happened, what the move to OTCQB means in practical terms, and what investors should genuinely be watching going forward.
The Short Answer — Zomedica Is Not Confirmed to Be Going Out of Business
As of the available evidence, Zomedica is still operating as a veterinary health company. The company continues to publish investor news releases and quarterly earnings results. No bankruptcy filing, liquidation notice, or closure announcement has been confirmed.
Around the time of the delisting, Zomedica reported a Q4 2024 EPS of -$0.01, meeting analyst estimates. That is not the behavior of a company that has shut down. It is a company still running operations and reporting financial results.
The key point here is simple: delisting and going out of business are two different events. Treating them as the same thing leads to the wrong conclusions.
What Actually Happened — NYSE American Delisting and the Move to OTCQB
NYSE American initiated delisting proceedings against Zomedica and suspended trading in its common shares. The exchange stated that Zomedica was no longer suitable for listing under its standards. This triggered an immediate trading suspension on that exchange.
In response, Zomedica announced a transition to the OTCQB Venture Market, effective March 5, 2025. The company’s shares now trade under the ticker ZOMDF on that platform.
This was a market relocation. The company did not file for bankruptcy, did not announce a shutdown, and did not undergo a corporate restructuring or sale. Its stock simply moved from one trading venue to another.
Delisting, Bankruptcy, and Business Closure Are Not the Same Thing
This is the most important distinction to understand, and it is worth spelling out clearly.
- Delisting means a company’s stock no longer trades on a specific exchange. It is a change in market status, not a legal or operational event.
- Bankruptcy is a formal legal process. It involves filing with a court for financial restructuring or liquidation. It is a significant legal step with defined procedures.
- Going out of business means a company has stopped operating entirely — no products, no employees, no services.
A company can be delisted and continue operating indefinitely. Many companies have traded on OTC markets for years while remaining fully functional businesses.
A useful way to think about it: imagine a retail store that moves from a large shopping mall to a smaller strip center down the road. The store still exists. It still sells products. Fewer people walk by, and it gets less attention — but it has not closed. That is roughly what a move from NYSE American to OTCQB looks like in business terms.
No bankruptcy filing or liquidation notice exists in the available evidence for Zomedica. The OTC market transition does not constitute a cessation of operations.
What the OTCQB Market Means for Zomedica Shareholders
OTCQB is a recognized marketplace for early-stage and developing companies. It is not the same as falling completely off the market. Shares can still be bought and sold under the ticker ZOMDF, and Yahoo Finance confirms the stock is actively listed there, with Zomedica described as a veterinary health company focused on companion animals.
That said, there are real practical differences from trading on NYSE American.
- OTC-listed stocks typically have lower liquidity than exchange-listed stocks, meaning fewer buyers and sellers at any given time.
- Bid-ask spreads tend to be wider, which can make buying and selling less efficient.
- Institutional investors and major funds often avoid OTC stocks due to internal policy restrictions, which reduces demand and analyst coverage.
- Reduced exchange standards generally mean less regulatory scrutiny, which carries its own risks for investors.
Importantly, the move does not strip shareholders of their equity. Existing shares remain valid. The company’s equity structure has not been dissolved. Investors still hold what they held before — just on a different trading platform.
Financial Risk Is Real, but Forecasting Models Are Not Proof of Failure
Some market analysis platforms flag Zomedica as carrying elevated financial distress risk over the next 24 months. These tools are worth noting, but they should be understood for what they are.
These are probabilistic screener models based on financial ratios. They use data like cash levels, debt, and revenue trends to estimate a likelihood of distress. They are not confirmed insolvency events. A high score on a bankruptcy-risk screener does not mean a company will file — it means the financial profile shares characteristics with companies that have historically struggled.
For context, Zomedica reported a Q4 2024 loss per share of -$0.01. That is a narrow loss, not a catastrophic one. The company is not posting large profitability figures, but it is also not the portrait of an organization in freefall.
What matters more than a screener result is whether the company continues to generate revenue, manage its cash, and operate its product lines. Those are the numbers worth tracking.
What Investors and Observers Should Actually Watch
If you want a meaningful read on Zomedica’s future, these are the indicators that carry real weight:
- Continued earnings reports: As long as Zomedica publishes quarterly results, it is still operating. A company that goes dark on financial reporting is a far more serious warning sign than a delisting.
- Revenue trends: Is the company growing, stabilizing, or declining in revenue? That tells you more about business health than the exchange it trades on.
- Cash position: For companies that are not yet profitable, cash runway is critical. Watch whether Zomedica has enough cash to fund operations over the next several quarters.
- Investor relations activity: Zomedica’s investor relations page continues to feature news releases. An active IR page is a basic but meaningful sign that the company is still engaged with its shareholders.
- Any formal filings: A bankruptcy filing or dissolution notice would be a formal, public event. Until that happens, claims that Zomedica is “going out of business” are not supported by confirmed evidence.
For broader context on how to evaluate companies going through market transitions like this one, Every Business Mag covers business news and financial topics that help readers make sense of events like these.
The Bottom Line
Zomedica was delisted from NYSE American and transitioned its shares to the OTCQB Venture Market under the ticker ZOMDF, effective March 5, 2025. That is the confirmed fact. What that event does not confirm is that Zomedica is bankrupt, shutting down, or ceasing operations.
The company was still reporting earnings and publishing investor materials around the time of the delisting. No formal insolvency or closure proceedings have been announced based on available evidence.
Financial risk is a legitimate concern for any company trading at low prices on an OTC market. But risk is not outcome. A delisting is a serious development that warrants attention — it is not, by itself, proof that a company is finished.
Watch the filings. Watch the cash. Watch whether the company keeps reporting. Those signals will tell you far more than the exchange it trades on.
Read Also:
